scholarly journals Short-Term Treatment with Sevelamer Increases Serum Fetuin-A Concentration and Improves Endothelial Dysfunction in Chronic Kidney Disease Stage 4 Patients

2007 ◽  
Vol 3 (1) ◽  
pp. 61-68 ◽  
Author(s):  
Kayser Caglar ◽  
Mahmut Ilker Yilmaz ◽  
Mutlu Saglam ◽  
Erdinc Cakir ◽  
Cengizhan Acikel ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Endothelial Dysfunction ◽  
Kidney Disease ◽  
Chronic Kidney Disease Stage ◽  
Term Treatment ◽  
Disease Stage ◽  
Short Term ◽  
Short Term Treatment ◽  
Fetuin A ◽  
Stage 4

Phosphate binders in patients with chronic kidney disease: Between the new and the old.

2019 ◽  
pp. 2-3
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Estimated Glomerular Filtration Rate ◽  
Chronic Kidney Disease Stage ◽  
Disease Stage ◽  
Phosphate Binders ◽  
Advanced Chronic Kidney Disease ◽  
Phosphate Retention ◽  
Stage 4 ◽  
Dietary Phosphate

Impaired phosphate excretion by the kidney leads to Hyperphosphatemia. It is an independent predictor of cardiovascular disease and mortality in patients with advanced chronic kidney disease (stage 4 and 5) particularly in case of dialysis. Phosphate retention develops early in chronic kidney disease (CKD) due to the reduction in the filtered phosphate load. Overt hyperphosphatemia develops when the estimated glomerular filtration rate (eGFR) falls below 25 to 40 mL/min/1.73 m2. Hyperphosphatemia is typically managed with oral phosphate binders in conjunction with dietary phosphate restriction. These drugs aim to decrease serum phosphate by binding ingested phosphorus in the gastrointestinal tract and its transformation to non-absorbable complexes [1].

scholarly journals Hubungan Gagal Ginjal Kronik Tingkat 4 Dan 5 Dengan Kejadian Dislipidemia Pada Pasien Gagal Ginjal Kronik Di Rumah Sakit Umum Pusat Fatmawati Periode Tahun 2016

2018 ◽  
Vol 12 (2) ◽  
Author(s):  
Dimas Farhan Wibawanto ◽  
Salman Paris ◽  
Maria Selvester Thadeus
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
High Density Lipoprotein ◽  
Low Density Lipoprotein ◽  
Chronic Kidney Disease Stage ◽  
Density Lipoprotein ◽  
Disease Stage ◽  
Low Density ◽  
Stage 4 ◽  
Relationship Of

Dyslipidemia is a common complication of chronic kidney disease. Dyslipidemia itself is a common risk for a cardiovascular disease, which is the leading cause of death in chronic kidney disease. This study aims to identify the relationship of chronic kidney disease stage 4 and 5 with the incidence of dyslipidemia at Fatmawati General Hospital in the period of 2016. Design cross-sectional with simple random sampling technique. Data were collected by looking at the patient's medical records. Respondents are 80 people. The study population were all patients diagnosed with chronic kidney disease at Fatmawati Central General Hospital in 2016. The results showed that most chronic kidney disease stage 4 has normal level of low density lipoprotein as many 22 people (73.33%) while at stage 5 most have high level of low density lipoprotein high as many 36 people (72%). High density lipoprotein obtained in patients with chronic kidney disease stage 4 mostly had normal level as many 20 people (66.67%) for stage 5 mostly had low level as many 33 people (66%). Mean lipid values of triglyceride X̄ = 152,36, high density lipoprotein X̄ = 39,36 and low density lipoprotein X̄ = 145,01. Result of bivariate analysis with chi square test showed significant relationship of chronic kidney disease stage 4 and 5 with incidence of dyslipidemia (p = 0,002).

scholarly journals Direct Evidence of Endothelial Dysfunction and Glycocalyx Loss in Dermal Biopsies of Patients With Chronic Kidney Disease and Their Association With Markers of Volume Overload

2021 ◽  
Vol 9 ◽  
Author(s):  
Josephine Koch ◽  
Ryanne S. Hijmans ◽  
Manuela Ossa Builes ◽  
Wendy A. Dam ◽  
Robert A. Pol ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Endothelial Dysfunction ◽  
Kidney Disease ◽  
Chronic Kidney Disease Stage ◽  
Volume Overload ◽  
Disease Stage ◽  
Hydration Status ◽  
Endothelial Markers ◽  
Markers Of Inflammation ◽  
Skin Biopsies

Cardiovascular morbidity is a major problem in patients with chronic kidney disease (CKD) and endothelial dysfunction (ED) is involved in its development. The luminal side of the vascular endothelium is covered by a protective endothelial glycocalyx (eGC) and indirect evidence indicates eGC loss in CKD patients. We aimed to investigate potential eGC loss and ED in skin biopsies of CKD patients and their association with inflammation and volume overload. During living kidney transplantation procedure, abdominal skin biopsies were taken from 11 patients with chronic kidney disease stage 5 of whom 4 were treated with hemodialysis and 7 did not receive dialysis treatment. Nine healthy kidney donors served as controls. Biopsies were stained and quantified for the eGC marker Ulex europaeus agglutinin-1 (UEA1) and the endothelial markers vascular endothelial growth factor-2 (VEGFR2) and von Willebrand factor (vWF) after double staining and normalization for the pan-endothelial marker cluster of differentiation 31. We also studied associations between quantified log-transformed dermal endothelial markers and plasma markers of inflammation and hydration status. Compared to healthy subjects, there was severe loss of the eGC marker UEA1 (P < 0.01) while VEGFR2 was increased in CKD patients, especially in those on dialysis (P = 0.01). For vWF, results were comparable between CKD patients and controls. Skin water content was identical in the three groups, which excluded dermal edema as an underlying cause in patients with CKD. The dermal eGC/ED markers UEA1, VEGFR2, and vWF all associated with plasma levels of NT-proBNP and sodium (all R2 > 0.29 and P < 0.01), except for vWF that only associated with plasma NT-proBNP. This study is the first to show direct histopathological evidence of dermal glycocalyx loss and ED in patients with CKD. In line with previous research, our results show that ED associates with markers of volume overload arguing for strict volume control in CKD patients.

Sign in / Sign up

Export Citation Format

Share Document